Comparison 5.
Secondary outcome ‐ quality of life
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Conventional systemic agents versus placebo | 2 | Std. Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 1.1 Methotrexate | 2 | 283 | Std. Mean Difference (IV, Random, 95% CI) | ‐0.67 [‐1.40, 0.06] |
| 2 Anti‐TNF alpha versus placebo | 14 | Std. Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 2.1 Etanercept versus placebo | 7 | 2779 | Std. Mean Difference (IV, Random, 95% CI) | ‐1.10 [‐1.37, ‐0.83] |
| 2.2 Adalimumab versus placebo | 7 | 2774 | Std. Mean Difference (IV, Random, 95% CI) | ‐1.02 [‐1.16, ‐0.88] |
| 3 Ustekinumab versus placebo | 6 | 2917 | Std. Mean Difference (IV, Random, 95% CI) | ‐1.21 [‐1.39, ‐1.03] |
| 4 Anti‐IL17 versus placebo | 5 | Std. Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 4.1 Ixekizumab versus placebo | 3 | 3126 | Std. Mean Difference (IV, Random, 95% CI) | ‐1.76 [‐2.09, ‐1.43] |
| 4.2 Brodalumab versus placebo | 2 | 349 | Std. Mean Difference (IV, Random, 95% CI) | ‐0.96 [‐1.44, ‐0.47] |
| 5 Anti‐IL23 versus placebo | 3 | Std. Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 5.1 Guselkumab versus placebo | 2 | 1252 | Std. Mean Difference (IV, Random, 95% CI) | ‐1.39 [‐1.63, ‐1.14] |
| 5.2 Tildrakizumab versus placebo | 1 | 355 | Std. Mean Difference (IV, Random, 95% CI) | ‐1.23 [‐1.55, ‐0.91] |
| 6 Other biologics | 2 | Std. Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 6.1 Alefacept versus placebo | 1 | 229 | Std. Mean Difference (IV, Random, 95% CI) | ‐0.32 [‐0.62, ‐0.02] |
| 6.2 Itolizumab versus placebo | 1 | 225 | Std. Mean Difference (IV, Random, 95% CI) | ‐0.34 [‐0.68, ‐0.01] |
| 7 Biologic versus conventional systemic treatments | 2 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only | |
| 7.1 Alefacept versus methotrexate | 1 | 212 | Mean Difference (IV, Fixed, 95% CI) | 1.31 [‐0.28, 2.90] |
| 7.2 Adalimumab versus methotrexate | 1 | 218 | Mean Difference (IV, Fixed, 95% CI) | ‐3.40 [‐5.75, ‐1.05] |
| 8 Biologic 1 versus biologic 2 | 4 | Mean Difference (IV, Fixed, 95% CI) | Subtotals only | |
| 8.1 Ixekizumab versus etanercept | 2 | 2209 | Mean Difference (IV, Fixed, 95% CI) | ‐1.99 [‐2.39, ‐1.59] |
| 8.2 Guselkumab versus adalimumab | 2 | 1407 | Mean Difference (IV, Fixed, 95% CI) | ‐1.73 [‐2.50, ‐0.97] |
| 9 Small molecules versus placebo | 7 | Std. Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 9.1 Apremilast versus placebo | 3 | 1609 | Std. Mean Difference (IV, Random, 95% CI) | ‐0.62 [‐0.77, ‐0.47] |
| 9.2 Tofacitinib versus placebo | 3 | 2629 | Std. Mean Difference (IV, Random, 95% CI) | ‐1.09 [‐1.28, ‐0.89] |
| 9.3 Ponesimod versus placebo | 1 | 326 | Std. Mean Difference (IV, Random, 95% CI) | ‐0.58 [‐0.86, ‐0.31] |
| 10 Biologic versus small molecules | 1 | Std. Mean Difference (IV, Random, 95% CI) | Subtotals only | |
| 10.1 Etanercept versus Tofacitinib | 1 | 998 | Std. Mean Difference (IV, Random, 95% CI) | ‐0.06 [‐0.19, 0.07] |